CL2016001362A1 - Composiciones y métodos para reducir eventos adversos cardiovasculares graves - Google Patents

Composiciones y métodos para reducir eventos adversos cardiovasculares graves

Info

Publication number
CL2016001362A1
CL2016001362A1 CL2016001362A CL2016001362A CL2016001362A1 CL 2016001362 A1 CL2016001362 A1 CL 2016001362A1 CL 2016001362 A CL2016001362 A CL 2016001362A CL 2016001362 A CL2016001362 A CL 2016001362A CL 2016001362 A1 CL2016001362 A1 CL 2016001362A1
Authority
CL
Chile
Prior art keywords
compositions
methods
adverse events
serious cardiovascular
cardiovascular adverse
Prior art date
Application number
CL2016001362A
Other languages
English (en)
Spanish (es)
Inventor
Preston Klassen
Kristin Taylor
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52575014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001362(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of CL2016001362A1 publication Critical patent/CL2016001362A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2016001362A 2013-12-06 2016-06-03 Composiciones y métodos para reducir eventos adversos cardiovasculares graves CL2016001362A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361913216P 2013-12-06 2013-12-06
US201361914938P 2013-12-11 2013-12-11
US201461984580P 2014-04-25 2014-04-25
US14/322,810 US8969371B1 (en) 2013-12-06 2014-07-02 Compositions and methods for weight loss in at risk patient populations

Publications (1)

Publication Number Publication Date
CL2016001362A1 true CL2016001362A1 (es) 2017-01-06

Family

ID=52575014

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001362A CL2016001362A1 (es) 2013-12-06 2016-06-03 Composiciones y métodos para reducir eventos adversos cardiovasculares graves

Country Status (33)

Country Link
US (8) US8969371B1 (sl)
EP (2) EP3076971B1 (sl)
JP (2) JP6665094B2 (sl)
KR (3) KR20230152800A (sl)
CN (3) CN114404419A (sl)
AU (1) AU2014360492A1 (sl)
BR (1) BR112016012755A2 (sl)
CA (1) CA2932127C (sl)
CL (1) CL2016001362A1 (sl)
CR (1) CR20160313A (sl)
CY (1) CY1125114T1 (sl)
DK (1) DK3076971T3 (sl)
EA (1) EA201690964A1 (sl)
EC (1) ECSP16057765A (sl)
ES (1) ES2903391T3 (sl)
HR (1) HRP20220058T1 (sl)
HU (1) HUE057551T2 (sl)
IL (3) IL300870A (sl)
JO (1) JOP20140344B1 (sl)
LT (1) LT3076971T (sl)
MX (2) MX2016007231A (sl)
PE (1) PE20161034A1 (sl)
PL (1) PL3076971T3 (sl)
PT (1) PT3076971T (sl)
RS (1) RS62846B1 (sl)
RU (1) RU2711638C2 (sl)
SG (1) SG10201808055QA (sl)
SI (1) SI3076971T1 (sl)
TN (1) TN2016000231A1 (sl)
TW (1) TWI661826B (sl)
UY (1) UY35864A (sl)
WO (1) WO2015085044A1 (sl)
ZA (1) ZA201603831B (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
ES2802048T3 (es) * 2012-06-06 2021-01-15 Nalpropion Pharmaceuticals Llc Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
US8969371B1 (en) * 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
BR112019002781A2 (pt) * 2016-08-11 2019-07-09 Huawei Tech Co Ltd método de comunicação sem fio, estação base e dispositivo terminal baseado em espectro não licenciado
WO2023107640A1 (en) * 2021-12-09 2023-06-15 Incarda Therapeutics, Inc. Inhaled therapy for cardiac arrhythmia

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
IL58649A (en) 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
DE3381877D1 (de) 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
DE3883606T2 (de) 1987-05-04 1994-01-20 Lilly Co Eli Verwendung von Fluoxetin zur Behandlung des Diabetes.
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
CA2197554A1 (en) 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
CA2220768A1 (en) 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
EP0795327A1 (en) 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
ES2277357T3 (es) 1996-05-07 2007-07-01 Veroscience Llc Metodo y compuesto para el tratamiento de desordenes de metabolismo de lipidos y glucosa.
ATE224189T1 (de) 1996-06-28 2002-10-15 Ortho Mcneil Pharm Inc Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
EP1019088B1 (en) 1997-10-03 2003-02-12 Cary Medical Corporation Composition for the treatment of nicotine addiction containing mecamylamine and bupropion
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
EP1215963A4 (en) 1999-09-15 2005-07-27 Elan Pharm Inc METHOD FOR THE TREATMENT OF NEUROPATHIC PAIN USING HETEROARYLMETHANSULFONAMIDES
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
CA2397726A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
DK2283842T3 (en) 2000-02-08 2015-05-26 Euro Celtique Sa Oral opioid agonist formulations secured against forgery
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
ATE396738T1 (de) 2000-09-18 2008-06-15 Sanos Bioscience As Verwendung von glp-2-peptiden
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
PT1414451E (pt) 2001-08-06 2009-07-31 Euro Celtique Sa Formulações agonistas de opióides com antagonista libertável e sequestrado
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
CN1320886C (zh) 2002-05-17 2007-06-13 杜克大学 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
EP1505974B1 (en) 2002-05-17 2009-04-22 Tioga Pharmaceuticals, Inc. Use of compounds that are effective as selective opiate receptor modulators
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
WO2004024096A2 (en) 2002-09-13 2004-03-25 Eisai Co., Ltd. Method of treating tremors
WO2004071423A2 (en) 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
WO2004091593A2 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
AU2004237951A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
ATE464049T1 (de) 2003-09-25 2010-04-15 Euro Celtique Sa Pharmazeutische kombinationen von hydrocodon und naltrexon
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
BRPI0510593A (pt) 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
JP2008509142A (ja) 2004-08-03 2008-03-27 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすためのブプロピオンと第２の化合物との組合せ
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
EP1954316A1 (en) 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
WO2007145863A2 (en) 2006-06-05 2007-12-21 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
PT2526932T (pt) 2006-06-19 2017-08-10 Alpharma Pharmaceuticals Llc Composição farmacêutica
CA2693992C (en) 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
KR101654176B1 (ko) 2006-11-09 2016-09-09 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
AU2011203867B2 (en) * 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
AU2011336298B2 (en) 2010-12-03 2017-03-02 Nalpropion Pharmaceuticals Llc Methods for reducing binge or compulsive eating
ES2802048T3 (es) * 2012-06-06 2021-01-15 Nalpropion Pharmaceuticals Llc Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
US8969371B1 (en) * 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
US10231964B2 (en) 2019-03-19
JP6665094B2 (ja) 2020-03-13
EP3076971A1 (en) 2016-10-12
JP2016539164A (ja) 2016-12-15
US9801875B2 (en) 2017-10-31
JP2020037593A (ja) 2020-03-12
NZ720620A (en) 2022-03-25
LT3076971T (lt) 2022-02-10
CR20160313A (es) 2018-01-26
IL282117A (en) 2021-05-31
TN2016000231A1 (en) 2017-10-06
US10835527B2 (en) 2020-11-17
MX2022001251A (es) 2022-02-23
PE20161034A1 (es) 2016-11-13
IL300870A (en) 2023-04-01
EA201690964A1 (ru) 2016-12-30
CN105899210A (zh) 2016-08-24
TW201607536A (zh) 2016-03-01
RS62846B1 (sr) 2022-02-28
TWI661826B (zh) 2019-06-11
DK3076971T3 (da) 2022-01-24
CN117159547A (zh) 2023-12-05
AU2014360492A1 (en) 2016-06-23
US20190314363A1 (en) 2019-10-17
US20150366860A1 (en) 2015-12-24
US20190374535A1 (en) 2019-12-12
EP3076971B1 (en) 2021-10-20
EP4005571A1 (en) 2022-06-01
CA2932127A1 (en) 2015-06-11
KR20160095076A (ko) 2016-08-10
US20160310485A1 (en) 2016-10-27
US10231962B2 (en) 2019-03-19
US20150182524A1 (en) 2015-07-02
ES2903391T3 (es) 2022-04-01
US20210069181A1 (en) 2021-03-11
US9119850B2 (en) 2015-09-01
IL245919A0 (en) 2016-07-31
CN114404419A (zh) 2022-04-29
EP3076971A4 (en) 2017-06-28
ZA201603831B (en) 2023-05-31
HUE057551T2 (hu) 2022-05-28
BR112016012755A2 (pt) 2017-08-08
US8969371B1 (en) 2015-03-03
KR102472432B1 (ko) 2022-11-30
ECSP16057765A (es) 2017-02-24
SI3076971T1 (sl) 2022-04-29
PL3076971T3 (pl) 2022-04-04
PT3076971T (pt) 2022-01-26
WO2015085044A1 (en) 2015-06-11
HRP20220058T1 (hr) 2022-04-15
UY35864A (es) 2015-07-31
JP7204634B2 (ja) 2023-01-16
MX2016007231A (es) 2016-08-04
CY1125114T1 (el) 2023-06-09
KR20230152800A (ko) 2023-11-03
SG10201808055QA (en) 2018-10-30
US10828294B2 (en) 2020-11-10
JOP20140344B1 (ar) 2021-08-17
CA2932127C (en) 2023-05-02
US20180243288A1 (en) 2018-08-30
RU2711638C2 (ru) 2020-01-17
KR20220165791A (ko) 2022-12-15

Similar Documents

Publication Publication Date Title
CL2016001362A1 (es) Composiciones y métodos para reducir eventos adversos cardiovasculares graves
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
UA118558C2 (uk) Пептидна сполука
BR112016017418A8 (pt) uso de copolímeros
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
UY36330A (es) Compuestos inhibidores de quinasa de unión a tank
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
BR112016029860A2 (pt) conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
DOP2014000098A (es) 2-tiopirimidinonas
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
CL2016000379A1 (es) Composiciones y métodos terapéuticos para reducción acelerada de plagas
EA201891628A1 (ru) Ингибирование аллергической реакции с использованием ингибитора il-33
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
CL2016001192A1 (es) Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.
UY35823A (es) Profármacos de antagonista de nmda